GOLD ABE Group (COPD) — free guideline decision tool
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does GOLD ABE Group (COPD) do?
Use to assign group A, B, or E and select initial inhaled therapy in stable COPD.
How is the result calculated?
Group E for ≥ 1 moderate exacerbation or ≥ 1 hospitalization in the past year (initial LABA+LAMA, consider ICS if eosinophils ≥ 300); otherwise group B (mMRC ≥ 2/CAT ≥ 10 → LABA+LAMA) or group A (low symptoms → single bronchodilator).
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run GOLD ABE Group (COPD) now
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.